Researchers developing new AI-powered solution for diabetes patients

Researchers from the University at Buffalo (UB) in New York are working to turn a $200,000 grant into groundbreaking diabetes research.

Tarunraj Singh, PhD, a professor from UB’s department of mechanical and aerospace engineering, is leading the group’s efforts. The researchers hope to use AI and freshly collected data to learn more about how stress and various activities can impact a person’s blood glucose.

“We’re developing new tools—combining data collected from diabetes-monitoring tools with AI systems, as well as traditional time-series modeling approaches—that could greatly improve how people manage their Type 1 diabetes,” Singh said in a news release from the university.

The data being used for this study comes from Tidepool, a nonprofit organization that anonymizes data from volunteers wearing glucose monitors. The team at UB hopes to use that data to validate the AI solution that will ultimately “provide people with diabetes a more nuanced analysis of their blood sugar.” The solution, according to the news release, will combine machine learning technology with a technique known as first principles thinking. It is still under development.

JDRF, a nonprofit known for funding diabetes research, provided Singh et al. with the $200,000 grant.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.